Platform Adaptive Embedded Trial for Acute Respiratory Distress Syndrome

• Status: Recruiting
• Trial end date: 2023-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Platform adaptive embedded trial for acute respiratory distress syndrome (PETARDS) is a randomized, embedded, multifactorial, adaptive platform trial for ARDS. The study aimed to assess the impact of multiple interventions on outcomes in patients with ARDS admitted to the ICU.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
• Collaborators: Fudan University; Guangdong Provincial People's Hospital; Ningbo No. 1 Hospital; Peking Union Medical College Hospital; Renmin Hospital of Wuhan University; Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University; The First Affiliated Hospital of Zhengzhou University; The Second Affiliated Hospital of Harbin Medical University; West China Hospital; Wuhan Union Hospital, China
• Treatments: Anti-Infective Agents; Bromides; Dexamethasone; Dexmedetomidine; Dopamine; Epinephrine; Glucocorticoids; Hydrocortisone; Hypnotics and Sedatives; Isoproterenol; Metaraminol; Midazolam; Norepinephrine; Olprinone; Propofol; Rosuvastatin Calcium; Simendan; Simvastatin; Succinylcholine; Vecuronium Bromide

Criteria

Inclusion Criteria:

Adult patients (18 years and older, regardless of gender) admitted to the ICU with ARDS; Intubation and mechanical ventilation; Moderate/severe ARDS defined by Berlin criteria (PaO2/FiO2 ≤200mmHg, PEEP ≥5cmH20); Moderate/severe ARDS less than 48 hours before randomization.

Exclusion Criteria:

Pregnancy or breastfeeding; Known allergy to the intervention drug; Daily use of an intervention drug or measure within the past 15 days; Intervention drugs or measures primarily intended to treat other conditions (eg, septic shock); Patients using the intervention drug or standard for two or more days during hospitalization; Patients are expected to die within the next 24 hours; Other: Participated in PETARDS in the past 90 days.